Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of BI 1820237 and Survodutide on Brain Activity in Obesity
NCT06352424Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of survodutide and BI 1820237 in obesity (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Blood Oxygen Level Dependent signal changes at 32 days. Started Apr 2024; status: completed.
02
Drugs
survodutideBI 1820237
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06352424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06352424.